Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
IRTC 
iRhythm Technologies Inc (IRTC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: IRTC (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $220.6
1 Year Target Price $220.6
| 9 | Strong Buy |
| 3 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 20.32% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.75B USD | Price to earnings Ratio - | 1Y Target Price 220.6 |
Price to earnings Ratio - | 1Y Target Price 220.6 | ||
Volume (30-day avg) 13 | Beta 1.1 | 52 Weeks Range 81.87 - 212.00 | Updated Date 12/6/2025 |
52 Weeks Range 81.87 - 212.00 | Updated Date 12/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -7.32% | Operating Margin (TTM) -2.08% |
Management Effectiveness
Return on Assets (TTM) -3.08% | Return on Equity (TTM) -53.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6065834317 | Price to Sales(TTM) 8.18 |
Enterprise Value 6065834317 | Price to Sales(TTM) 8.18 | ||
Enterprise Value to Revenue 8.63 | Enterprise Value to EBITDA -34.37 | Shares Outstanding 32219143 | Shares Floating 31865699 |
Shares Outstanding 32219143 | Shares Floating 31865699 | ||
Percent Insiders 0.83 | Percent Institutions 111.06 |
Upturn AI SWOT
iRhythm Technologies Inc
Company Overview
History and Background
iRhythm Technologies, Inc. was founded in 2006. It focuses on developing medical devices and solutions for cardiac arrhythmia monitoring. Its flagship product is the Zio XT, a wearable sensor for long-term heart monitoring. Over the years, it has evolved from a startup to a publicly traded company.
Core Business Areas
- Ambulatory Cardiac Monitoring: Provides long-term continuous cardiac monitoring using wearable sensors and cloud-based analytics to detect and diagnose arrhythmias.
Leadership and Structure
The leadership team includes Quentin Blackford as CEO. The organizational structure is typical of a medical device company, with departments focused on R&D, manufacturing, sales, marketing, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Zio XT: A wearable, single-use sensor that continuously records ECG data for up to 14 days. This data is then analyzed using proprietary algorithms to detect and classify arrhythmias. Competitors include Medtronic (MDT), Boston Scientific (BSX), and Abbott (ABT). Market share estimated around 25% within the ambulatory cardiac monitoring segment.
Market Dynamics
Industry Overview
The cardiac monitoring industry is growing, driven by an aging population, increasing prevalence of heart disease, and technological advancements in wearable sensors and AI-powered analytics.
Positioning
iRhythm Technologies is positioned as a leader in ambulatory cardiac monitoring, particularly known for its Zio XT patch and its AI-driven data analysis capabilities. It differentiates itself through patient convenience and data accuracy.
Total Addressable Market (TAM)
The global cardiac monitoring market is expected to reach tens of billions of dollars. iRhythm is positioned to capture a significant portion, particularly within the long-term ambulatory monitoring segment.
Upturn SWOT Analysis
Strengths
- Proprietary AI algorithms for data analysis
- Convenient wearable sensor design
- Strong brand reputation
- Large database of ECG data for improved accuracy
Weaknesses
- Reliance on reimbursement approvals
- High manufacturing costs
- Competition from established medical device companies
- Dependence on single flagship product
Opportunities
- Expansion into new geographic markets
- Development of new cardiac monitoring solutions
- Partnerships with healthcare providers and payers
- Integration of AI into other areas of cardiology
Threats
- Changes in reimbursement policies
- Emergence of new competitors
- Technological obsolescence
- Data security and privacy concerns
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
- GEHC
Competitive Landscape
iRhythm's advantages lie in its specialized focus and AI capabilities. However, it faces competition from larger, diversified medical device companies with broader portfolios and established relationships with healthcare providers.
Growth Trajectory and Initiatives
Historical Growth: iRhythm has experienced rapid revenue growth driven by adoption of its Zio XT platform.
Future Projections: Analysts project continued revenue growth, but profitability is expected to be a key focus. Expansion into new markets and product development are anticipated.
Recent Initiatives: Recent initiatives include expanding the sales force, investing in R&D, and pursuing regulatory approvals for new products and services.
Summary
iRhythm Technologies is a growth-oriented company specializing in cardiac monitoring. It has shown strong revenue growth and innovation in AI-driven data analysis. However, challenges include reimbursement pressures and competition from larger players. Future success hinges on expanding market share and achieving profitability.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Estimates
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About iRhythm Technologies Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2016-10-20 | President, CEO & Director Mr. Quentin S. Blackford | ||
Sector Healthcare | Industry Medical Devices | Full time employees 2000 | Website https://www.irhythmtech.com |
Full time employees 2000 | Website https://www.irhythmtech.com | ||
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.